Ascentage Pharma Group Corporation

New clinical data for Ascentage’s lisaftoclax support its further development in combination with azacitidine for acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS), the Chin

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a